Loading
Seventeen years after a single flexible sigmoidoscopy, the protection was still there: a quarter fewer bowel cancers and a third fewer deaths.
Atkin, Wooldrage, Parkin and colleagues extended the UK Flexible Sigmoidoscopy Screening Trial, run between November 1994 and March 1999, to a median 17.1 years of follow-up in 170,034 people: 112,936 controls and 57,098 in the intervention group, of whom 40,621 (71 percent) were screened.
Colorectal cancer was diagnosed in 1,230 people in the intervention group and 3,253 in the control group, and 353 against 996 died of it. The protection from one examination did not wane over the whole observation period, which is the finding that matters for how often screening endoscopy needs to be repeated.
Durability is what makes endoscopic screening cost-effective: one procedure at 55 buys nearly two decades of protection, which is the argument for long intervals rather than frequent tests.
Shares UK gap: match endoscopy capacity and quality to the faecal immunochemical test thresholds the NHS has already set, Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The hardest cancers are found late and the tag colorectal-evidence.
Shares Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The Lancet, The hardest cancers are found late and the tag colorectal-evidence.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The Lancet, The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares UK gap: match endoscopy capacity and quality to the faecal immunochemical test thresholds the NHS has already set, Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The hardest cancers are found late and the tag colorectal-evidence.
Shares National Institute for Health and Care Excellence, Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Cancer Research UK, The hardest cancers are found late and the tag colorectal-evidence.
Shares Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.